Quick Answer
DEXCOM INC reported Cash and Equivalents of $917.70 million for fiscal year 2025.
DEXCOM INC Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $917.70M | +51.4% |
| 2024 | $606.10M | +7.0% |
| 2023 | $566.30M | -11.8% |
| 2022 | $642.30M | -39.0% |
| 2021 | $1.05B | +28.7% |
| 2020 | $817.60M | +83.2% |
| 2019 | $446.20M | -60.8% |
| 2018 | $1.14B | +157.5% |
| 2017 | $441.50M | +367.2% |
| 2016 | $94.50M | +9.8% |
| 2015 | $86.10M | +19.9% |
| 2014 | $71.80M | +66.2% |
| 2013 | $43.20M | +433.3% |
| 2012 | $8.10M | +211.5% |
| 2011 | $2.60M | -46.9% |
| 2010 | $4.90M | +36.1% |
| 2009 | $3.60M | -71.7% |
| 2008 | $12.70M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.84B | +195.5% | +58.4% |
| June 30, 2025 | $1.16B | +23.4% | +28.1% |
| March 31, 2025 | $904.90M | +6.3% | +49.3% |
| December 31, 2024 | $606.10M | +7.0% | -2.4% |
| September 30, 2024 | $621.20M | -3.5% | -33.9% |
| June 30, 2024 | $939.20M | -21.4% | +10.3% |
| March 31, 2024 | $851.20M | +36.6% | +50.3% |
| December 31, 2023 | $566.30M | -11.8% | -12.0% |
- DEXCOM INC showed an increase of +51.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, DEXCOM INC’s cash and equivalents has grown by 7126.0% (from $12.70 million to $917.70 million).
- The most recent figure is from DEXCOM INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: